Introduction
e whole plant of Phyllanthus debilis Linn. (Euphorbiaceae) -in Sinhala, ela-pitawakka or bimnelli; in Tamil, kilanelli -is used as a component of several compound decoctions recommended by Ayurvedic medicine in Sri Lanka. It is a small perennial weed about 30 to 60 cm long with the stem often branched at the base and with angular, glabrous leaf-bearing branches and blooms with owers of 6 sepals and sharp apical antler (Jayaweera, 1981) . It is widely distributed in Sri Lanka and in the subtropics except Australia.
P. debilis has been used in the Ayurvedic system of medicine for over 200 years and has a wide number of traditional uses. In Sri Lanka, all parts of the plants are used to treat several diseases.
e fresh roots of P. debilis is used as an excellent remedy for jaundice and diarrhea, while the milky juice is e ective in treatment of o ensive sores and the fruits are useful in tubercular ulcers, wounds, sores, bruises, scabies and ringworm. Further, the juice of the whole plant is given for gonorrhea and a paste made from ground-up plant is given with cow's milk for jaundice. In India, the whole plant is used as a diuretic in dropsical a ictions, gonorrhea and for other troubles of the urogenital tract, while young shoots are given for dysentery. In Sri Lanka, it is often recommended for the treatment of diabetes mellitus (Jayaweera, 1981) .
Diabetes mellitus remains the most common disorder of hereditary and carbohydrate metabolism (Kumar & Clark, 1999; Rang & Dale, 1987) . It is becoming an increasing problem worldwide and the highest rate of Type I diabetes mellitus is found in northern European countries and is more common in children under 5 years (Kumar & Clark, 1999) . Type II diabetes mellitus is common in African and South Asian counties. In Sri Lanka, at present, about 1 million people are diabetic, and more young people are becoming victims of the disease (Wijesuriya, 1997) . Most of the currently used allopathic antidiabetic drugs are expensive and also have several side e ects. Hence, there is a need to develop safe, orally active inexpensive antidiabetic drugs. ough the whole plant of P. debilis is used in Sri Lankan traditional medicinal system, the plant has not been scienti cally tested for the claimed diabetic activity. Further, its side e ects were not scienti cally examined. Hence, the present study examined the potential antidiabetic property and possible toxic e ects in normoglycemic mice using oral administration of aqueous plant extract (APE). 
Materials and methods

Plant material
Preparation of APE
Freshly collected plants were washed carefully, cut into small pieces and air-dried in the shade. Dried plant pieces (60 g) were boiled with 1920 mL of distilled water (DW) for 4-5 h. e hot extract was concentrated under vacuum at 60°C and freeze-dried at -70°C and stored at 4°C until use.
Oral administration of APE
Doses of 497.5, 995, and 1990 mg/kg of APE were prepared by dissolving freeze-dried powder in 1 mL of DW and gavaged to separate groups (n = 9 per group for both APE and DW) of mice. e mid-dose tested was 15 times higher than what is usually recommended by traditional practitioners of Sri Lanka in prescribing herbal decoctions, which is within the accepted range for the mice model (Dhawan & Srimal, 2000) .
Animals
Healthy adult male ICR mice (weighing 35-45 g) were used for all the experiments. Mice were kept in plastic cages and housed under standard animal house conditions (temperature: 28-31°C, photoperiod approximately 12 h natural light per day, and relative humidity 55-60%) with free access to pelleted food (Ceylon Grain Elevators, Colombo, Sri Lanka) and tap water. e research was conducted in accordance with the internationally accepted principles for animal use and care and guidelines and rules of the Faculty of Science, University of Colombo for animal experimentations. All surgical interventions were done under ether anesthesia using aseptic precautions.
E ects of APE on fasting and random blood glucose levels
Forty-ve mice were fasted overnight for 16 h with free access to water. Using aseptic precautions, under light ether anesthesia, blood (0.5 mL) was collected from tails of these mice. Subsequently, mice were randomly assigned into 5 groups and 1 mL of each solution was gavaged (n = 9/group) in the following manner: group I DW; group II 497.5 mg/kg APE; group III 995 mg/kg APE; group IV 1990 mg/kg APE and group V 33.5 mg/kg tolbutamide. Blood samples were collected from tails of these mice at 1, 3, and 5 h post treatment. Blood was allowed to clot for 10 min at room temperature and centrifuged at 3000 rpm for 5 min. e glucose concentrations in the serum samples were analyzed immediately by the glucose oxidase method using a Randox assay kit (Randox Laboratories, Antrim, UK) and a spectrophotometer (V500, Jasco Corporation, Tokyo, Japan) at 500 nm.
To investigate the e ect of APE on random glucose levels, the above-mentioned methodology was followed without fasting the mice. e doses used were 1 mL DW, 1 mL of 995 mg/kg APE and 1990 mg/kg APE (n = 6/group).
E ect of APE on oral glucose and sucrose tolerance
ese experiments were carried out using 1990 mg/kg of APE since the maximum hypoglycemic activity was evident with this dose in normoglycemic fasted mice. Twenty-four mice were fasted for 16 h and randomly divided into 4 equal groups. Two groups were treated with 1 mL DW and the other 2 groups were treated with 1 mL of 1990 mg/kg APE (n = 6/group). One hour later, these mice were orally loaded either with 3 g/kg glucose (Okine et al., 2005) or 2 g/kg sucrose (Fujita & Yamagami, 2001) solutions. Blood samples were collected from the tails of these mice and serum glucose level was measured prior to the treatment and at 1, 3, and 5 h after glucose and sucrose challenges.
Determination of mechanisms of hypoglycemic activity
e mechanism of hypoglycemic activity was investigated using 1990 mg/kg of APE since the maximum hypoglycemic activity was evident with this dose.
E ect of APE on glucose absorption from intestine
Twelve equally weighted mice were fasted for 16 h and divided randomly into two equal groups (n = 6/group) and the animals were orally treated either with 1 mL DW or 1990 mg/kg APE. irty minutes later, animals were orally loaded with 10 mL/kg of 50% glucose (Ratnasooriya et al., 2004) . After 2 h these animals were sacri ced with chloroform and their small intestines were exposed; 5 mL DW was then infused from one cut end of the intestine and the content was collected at the other end. is was centrifuged at 3000 rpm for 5 min and the supernatant was removed. Glucose levels in the supernatant were then estimated using a Randox kit and a spectrophotometer at 500 nm (Dharmasiri, 2001 ).
E ect of APE on liver and skeletal muscle glycogen content
Eighteen mice were fasted for 16 h and divided randomly into two equal groups (n = 9/group). Animals were orally treated either with 1 mL of DW or 1990 mg/mL of APE for 30 consecutive days. On day 1 post-treatment, animals were sacri ced with chloroform and portions of liver and the skeletal muscles were removed and blotted free of blood. Glycogen content in the liver and in the skeletal muscles was determined as described by Dharmasiri (2001) . Brie y, 100 mg of each organs (liver and skeleton muscles) was separately digested with 2 mL of 30% KOH and allowed to cool. Subsequently, 3 mL of 95% ethanol were added and heated until bubbles were formed. ese were cooled and centrifuged at 1000 rpm for 5 min and the supernatant was discarded. e residues were dissolved in 5 mL DW after several washing steps and treated with 4 mL anthrone reagent and immersed in an ice bath, to prevent excessive heating. Tubes were incubated at 100°C for 4 min for color development and immersed again in an ice bath. Absorbance was measured at 620 nm using a spectrophotometer (Seifter et al., 1950) .
E ects of APE on diaphragm uptake of glucose
Eighteen mice were randomly assigned into two equal groups (n = 9/group). ese animals were orally treated either with 1 mL DW or 1990 mg/kg APE for 30 consecutive days. Following treatment, mice were sacri ced with chloroform and diaphragms were removed and immediately washed with Krebs-Ringers bu er (KRB). Glucose uptake was estimated using the method described by Okine et al. (2005) . Brie y, diaphragms were immersed in Bovine serum albumin (BSA) (2% w/v) supplemented KRB containing 1 g/L glucose and incubated in a CO 2 incubator (Sanyo Electric Corporation, Tokyo, Japan) for 30 min. e incubation medium was removed and the glucose concentration was then estimated using a Randox kit and a spectrophotometer at 500 nm.
Toxicological studies
Adult mice were randomly divided into two groups (n = 9/group) and orally treated either with 1 mL DW or 1990 mg/kg APE daily for 30 consecutive days (between 9 and 10 a.m.). e animals were observed daily (between 11 a.m. and 12 noon) for any overt toxicity signs (salivation, diarrhea, lacrymation, tremors, ataxia, yellowing of fur, loss of fur, postural abnormalities or behavioral changes), stress (fur erection and exophthalmia), aversive behaviors (biting paw or penis, intense grooming behavior, scratching behavior and licking at tail) and mortality. In addition, percentage of body weight gain, and food and water intake were determined weekly during the period of treatment. Color of urine and consistency of feces were also noted during this period.
On day 1 post-treatment, approximately 2 mL blood was collected under mild ether anesthesia using aseptic precautions and divided into two equal parts. To one part blood, EDTA was added, and total red blood cell (RBC), total white blood cell (WBC) and di erential white blood cell (WBC/DC) counts were determined using standard procedures (Ghail, 1993) . Other part was allowed to clot for 25-30 min at room temperature (28-30°C) and centrifuged at 3000 rpm for 5 min. Serum samples were analyzed for concentrations of urea, creatinine, GOT, GPT, HDL cholesterol, LDL cholesterol, triglycerides and total cholesterol levels using respective Randox enzyme kits (Randox Laborotories, Antrim, UK) and a spectrophotometer.
After drawing blood, mice were sacri ced with chloroform and weighed. e liver, kidneys, testes, heart and spleen were removed, blotted free of blood, and wet weights were recorded. e weights of the organs were expressed as a percentage of the body weight. Parts of kidney and liver were xed in Bouin's solution and histological sections were prepared and stained with hemotoxylin and eosin stains (Humason, 1961) Subsequently, the slides were examined under high power (× 400) using a phase contrast microscope (Nikon Corporation, Tokyo, Japan) for pathological changes.
Statistical analyses
Data were expressed as mean ± SEM. Statistical comparisons were carried out using one-way ANOVA, followed by Kuskal-Wallis tests and Mann-Whitney U-test using Minitab 11 for Windows. e P value was set to ≤ 0.05.
Results
E ects of APE on fasting and random blood glucose levels
e e ect of APE of P. debilis on the fasting blood glucose level is shown in Table 1 . e high dose (1990 mg/kg) of APE signi cantly (p < 0.01) reduced the fasting blood glucose levels by 42% and 23% at 3 and 5 h, respectively, while the mid-dose reduced the glucose level signi cantly (p < 0.05) by 14% at 3 h only. e low dose (497.5 mg/kg) of APE had no signi cant (p > 0.05) e ect on blood glucose level. e impairment of blood glucose levels by APE was dose-dependent (APE: r 2 = 0.9994; p < 0.05). e maximum hypoglycemic activity was induced by 1990 mg/kg of APE at 3 h. Hypoglycemic activity of tolbutamide, the reference drug, was comparable to that of the 1990 mg/kg dose of APE. Similar to the high dose, the reference drug also signi cantly (p < 0.05) suppressed the glucose level from 1-5 h. In contrast, the APE did not show any signicant (p > 0.05) e ect on random blood glucose level.
E ect of APE on glucose and sucrose tolerance tests
e high dose of APE signi cantly (p < 0.01) improved the glucose tolerance test up to 5 h ( Figure 1A ). APE showed approximately 13%, 46%, and 51% reduction in glycemia from control values at 1, 2, and 3 h respectively. Further, APE signi cantly (p < 0.01) improved the sucrose tolerance at 3 and 5 h (32 and 25%, respectively) when compared to the control values ( Figure 1B ).
E ect on glucose absorption from intestine
APE treatment signi cantly (p < 0.01) inhibited the glucose absorption from the lumen of the intestine (control versus treatment: 24.21 ± 0.96 versus 47.55 ± 1.25 mg/dl). Glucose absorption was inhibited by 49% when compared to the control value.
E ect of liver and skeletal muscle glycogen content
Chronic treatments with 1990 mg/kg APE showed no e ect on both liver (control versus treatment:
2.31 ± 0.11 versus 2.50 ± 0.09 µg/100 mg) and skeletal muscle (control versus treatment: 0.99 ± 0.13 versus 1.23 ± 0.17 µg/100 mg) glycogen content.
E ect of diaphragm uptake of glucose
Chronic treatment with 1990 mg/kg of APE did not increase the diaphragm uptake of glucose as compared to the control group (control versus treatment: 8.34 ± 0.89 versus 7.52 ± 0.85 mg/dl). 
Toxicological studies
No deaths were observed with the APE. Further, animals did not show any overt signs of toxicity, stress, or aversive behaviors. Similarly, there was no signi cant (p > 0.05) suppression in percentage body weight and water or food intake (data not shown). e consistency of feces and color of urine of APE-treated mice were essentially similar to those of controls.
Further, treatment with 1990 mg/kg APE showed no renotoxicity (serum urea: control versus treatment; 56.98 ± 0.86 versus 52.07 ± 0.96 mg/dl and serum creatinine: control versus treatment; 0.85 ± 0.06 versus 0.89 ± 0.05 mg/dl) or hepatotoxicity (SGOT: control versus treatment; 28.55 ± 1.94 versus 28.36 ± 2.39 mg/dl and SGPT: control versus treatment; 28.20 ± 0.52 versus 24.35 ± 0.41 mg/dl). Neither changes in the wet weight of the main body organs nor in liver and kidney pathology were observed (data not shown).
As shown in Figure 2 , the RBC count in the APEtreated mice was signi cantly (p < 0.05) increased by 33% (control versus treatment: 2.3 × 10 5 ± 44029 versus 3.6 × 10 5 ± 14389 mm 3 ). Further, chronic daily treatment with 1990 mg/kg dose of APE signi cantly (p < 0.01) increased (by 17%) the HDL-cholesterol level but did not alter other parameters of the lipid pro le (Figure 3) .
Discussion
e present study showed that APE of P. debilis possesses both hypoglycemic and anti-hyperglycemic activities in fasted normoglycemic mice. e e ect lasted for 5 h and was dose-dependent. At 3 h, the hypoglycemic e ect of APE was superior to the tolbutamide. However, the random blood glucose level remained unaltered and similar results have been reported with stem bark of Cassia stula Linn. (Leguminocae) (Ratnasooriya et al., 2004 ) but the reason is not yet fully understood.
APE showed marked improvement of the glucose tolerance test and this indicates that P. debilis either has an insulin mimetic activity or can act on the pancreas to increase insulin secretion or both. Similarly, APE showed improvement in sucrose tolerance and caused marked inhibition of glucose uptake by the small intestine. Improvement of sucrose tolerance may be due to -glycosidase inhibitory activity (Coulson, 1995) present in APE. e drug may be competing with sucrose for its substrate, and binds to -glycosidase enzymes, thus leading to inhibition of sucrose digestion (Teixeira et al., 2007) . e APE had a gummy viscous appearance, thus it is possible that inhibition of intestinal glucose absorption is mediated via so called " ber e ect" (Ali et al., 1995; MacSweeney et al., 1995) .
is gummy appearance may be due to the presence of bers in the APE that are known to inhibit intestinal glucose absorption (Ali et al., 1995) . On the other hand, this inhibition of intestinal glucose absorption may result from impairment of gut Na + glucose co-transporters as reported with synthetic phlorizin derivative (Oku et al., 2000) . is indicates that the blood glucose lowering mechanism of P. debilis could be either due to inhibition of glucose absorption or its insulinomimetic and/or insulin secretagogue actions. Further, improvement of the sucrose tolerance test also indicates that the APE can inhibit intestinal -glucosidase enzyme activity. Similar results were obtained for some herbal drugs such as Salacia reticulata Linn. (Hippocrateaceae) (Yoshikawa et al., 1997) .
Photochemical analysis of some Phyllanthus species that have antioxidant activity showed the presence of avonoids in the extract (Kumaran & Karunakaran, 2007) and some other aqueous plant extracts with avonoids also possess antioxidant activities (Badami et al., 2003) to scavenge reactive oxygen species formed in chronic diabetes (Allen & Hamilton, 1983) . erefore, the hypoglycemic action of P. debilis may also result from avonoids in the APE. Flavonoids are useful in treatment of diabetes mellitus (Jaouad et al., 2003) . ere were no overt signs of toxicity, hepatotoxicity (in terms of SGPT and SGOT), or renotoxicity (in terms of serum urea and creatinine) following chronic administration of APE. Interestingly, APE elevated the RBC count, but in contrast to another species (Phyllanthus amarus Schum.), APE of P. debilis did not lower the plasma cholesterol level (Adeneye et al., 2006) . Instead, P. debilis increased HDL-cholesterol level. A similar elevation of HDL-cholesterol levels was observed by Shirwaikar et al. (2007) with an alcohol root extract of Holostemma annulare Schum. (Asclepiadaceae) and this is a very desirable biochemical state for the prevention of atherosclerosis and ischemic conditions, since long duration of diabetes mellitus is associated with complications such as myocardial dysfunctions and atherosclerosis (Shirwaikar et al., 2007) . Elevation of RBC is a therapeutically important nding which needs further study. is is important as P. debilis could be used in treatment of anemic diabetic patients.
is study has shown that P. debilis possesses marked antidiabetic activity with minimal toxicity. Its antidiabetic activity can be attributed to insulinomimetic or increased insulin secretion from the pancreas and the presence of gummy nature in the aqueous plant extract. Since there was no e ect on glycogen content in the liver or skeletal muscles and diaphragm uptake of glucose, it is evident that the action of APE of P. debilis is short term rather than long term. Finally, it can be concluded that P. debilis is an orally active safe drug with anti-diabetic potential and with the ability to elevate HDL cholesterol levels and RBC count.
